Nov 9, 2023

Dear Notable Community,

With the merger of Notable Labs and VBL Therapeutics completed and with NTBL publicly trading on NASDAQ, I would like to officially welcome and thank YOU – the newly combined group of shareholders, partners, employees, interested onlookers and all stakeholders – for your support in achieving these milestones. I am excited about the prospect of jointly advancing our patient-focused mission.

With cancer having touched my own family, my journey to Notable carries with it a very personal understanding of the disease and appreciation of Notable’s PPMP, our proprietary Predictive Precision Medicines Platform, and its ability to predict, before treatment, whether a patient will clinically respond to their treatment (or not).

Predicting a patient’s clinical response can match treatments with the patients who will most likely respond, ensuring medical benefit for them and protecting the other patients, who traditionally would have been treated but not responded, from losing time, experiencing toxicity, and wasting resources. At Notable, we believe each and every patient deserves a treatment that will work for them.

Beyond improving patient outcomes, predicting treatment response advances the development of novel medicines. Selectively enrolling predicted responders into clinical trials canmake trials more likely to succeed and be smaller, faster, and less costly. Bringing better medicines to patients faster and more predictably benefits all concerned.

Fueled by the integrated resources of two companies, our team is laser-focused on delivering several clinical milestones of the Volasertib and Fosciclopirox programs between now and 1Q 2025, expanding our recent strong results of four clinical validation studies in partnership with Stanford University, MD Anderson Cancer Center, and other recognized institutions.

I would also like to enthusiastically welcome our new Board Directors to Notable – industry leaders who have founded, led, financed, and sold some of the most revolutionary and successful biopharmaceutical and life science companies. Their passion, diverse expertise, and commitment to our mission and vision will be a tremendous asset to maximizing Notable’s impact for patients and stakeholders.

Please do not hesitate to reach out – we always welcome your input as well as opportunities to collaborate. I look forward to a continuous dialogue with you as we launch a new era of Predictive Precision Medicine together.

Thank you,

Thomas Bock